CASE REPORT
Relapse of polymyalgia rheumatica after a fall
More details
Hide details
Submission date: 2017-08-24
Final revision date: 2017-10-04
Acceptance date: 2017-10-18
Online publication date: 2017-10-28
Publication date: 2017-10-31
Reumatologia 2017;55(5):251-255
KEYWORDS
TOPICS
ABSTRACT
Approximately half of PMR patients have a relapse with a necessity to increase GC dosages. The role of external factors in inducing PMR relapse have been poorly investigated.
We present a case-series of five PMR patients in remission with low doses of glucocorticosteroids (GC), who presented with relapse immediately after a fall. The assessment of PMR relapse was made using PMR-AS by Leeb and Bird, and a score > 9.35 was consistent with diagnosis of relapse. Gender, age, and cumulative dose of GC at the time of the fall were compared between the group of these five patients and a group of 41 PMR patients who had no PMR relapse after a fall: using the Fischer’s exact test a significant difference was pointed out when the p-value was < 0.05. In our five PMR patients, the sharp worsening of clinical manifestations was always accompanied by a significant rise of the inflammatory indices and the increase of GC dosage (almost always 10 mg/day of prednisone) prompted a fast return (seven days as average) to the previous clinical and laboratory features. All other potentially responsible factors were excluded. Several months (6–10 months on average) after the fall, none of these five patients had a new relapse. No significant differences were found when we compared age, sex, and the cumulative dose of GC at the time of the fall between the group of patients with PMR relapse and the group of patients without.
The possibility of PMR relapse being realised immediately after a fall should be kept in mind in daily practice, especially when typical manifestations reappear immediately after a fall and other diagnostic hypotheses have been carefully excluded. The lack of important data (genetic factors, hormonal dosages, serum levels of IL-6 and/or serum soluble IL-6 receptor) in our case-series represented important limits for clarifying the nature of our observations and should be included in any subsequent study design on this argument. If our monocentric data are confirmed by multicentric data, the assessment of the risk of falls through specific scales should be an integral part of the visit of all PMR patients.
REFERENCES (22)
1.
Rooney PJ, Rooney J, Balint G, et al. Polymyalgia rheumatica: 125 years of epidemiological progress? Scottish Med J 2015; 60: 50-57.
2.
Manzo C, Natale M, Cappiello F. Quanti anziani con Polimialgia Reumatica passano sotto gli occhi del medico del territorio? Ger Extraosp 2008; VI: 12-15.
3.
Bird HA, Leeb BF, Montecucco CM, et al. A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatic. Ann Rheum Dis 2005; 64: 626-629.
4.
Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71: 484-492.
5.
Ellis ME, Ralston S. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis 1983; 42: 168-170.
6.
Manzo C, Camellino D. La polimialgia reumatica: difficoltà diagnostiche e terapeutiche per una malattia apparentemente “banale”. Recenti Prog Med 2017; 108: 221-231.
7.
Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015; 74: 1799-1807.
8.
Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population based cohort of patients with polymyalgia rheumatic. J Rheumatol 2005; 32: 65-73.
9.
Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, et al. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 2009; 169: 1839-1850.
10.
Weyand CM, Fullbright JW, Evans JM, et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999; 159: 577-584.
11.
Pulsatelli L, Boiardi L, Pignotti E, et al. Serum interleukin-6 receptor in polymyalgia rheumatica. Arthritis Rheum 2008; 59: 1147-1154.
12.
Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet 2013; 381: 63-72.
13.
Cutolo M, Straub RH. Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease. Clin Exp Rheumatol 2000; 18: 655-658.
14.
Straub RH, Gluck T, Cutolo M, et al. The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumor necrosis factor) in polymyalgia rheumatica. Rheumatology 2000; 39: 624-631.
15.
Tshimologo M, Saunders B, Muller S, et al. Patients’ views on the causes of their polymyalgia rheumatica: a content analysis of data from the PMR Cohort Study. BMJ Open 2017; 7 (1): e014301.
16.
Dejaco C, Duftner C, Cimmino MA, and members of the International Work Group for PMR and GCA. Polymyalgia rheumatica: clinical update. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011; 70: 447-453.
17.
Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatic. Ann Rheum Dis 2004; 63: 1279-1283.
18.
Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261-271.
19.
Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011; 78: 41-44.
20.
Vanhaecke Collard C, Drame M, Novella JL, et al. Functional manifestations associated to corticosteroid therapy among the elderly. Rev Med Interne 2012; 33: 358-363.
21.
Raîche M, Hébert R, Prince F, Corriveau H. Screening older adults at risk of falling with the Tinetti balance scale. Lancet 2000; 356: 1001-1002.
22.
Prusinowska A, Komorowski A, Sadura-Sieklucka T, et al. Risk of falls in the rheumatic patient at geriatric age. Reumatologia 2017; 55: 88-93.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.